Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Generated: September 17, 2019

DrugPatentWatch Database Preview

Patent: 9,938,273

Try a free trial

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,938,273

Title:	Compounds and methods for kinase modulation, and indications therefor
Abstract:	Disclosed are compounds of Formula I: ##STR00001## or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Z.sup.2, Z.sup.3, and Z.sup.5 are as described herein, compositions thereof, and uses thereof.
Inventor(s):	Wu; Guoxian (Foster City, CA), Wu; Jeffrey (Berkeley, CA), Chan; Katrina (Fremont, CA), Dong; Ken (Berkeley, CA), Ewing; Todd (Walnut Creek, CA), Ibrahim; Prabha N. (Mountain View, CA), Lin; Jack (Hercules, CA), Spevak; Wayne (Berkeley, CA), Zhang; Ying (Fremont, CA)
Assignee:	Plexxikon Inc. (Berkeley, CA)
Application Number:	15/370,631
Patent Claims:	see list of patent claims

Details for Patent 9,938,273

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Merck	ELSPAR	asparaginase	VIAL	101063	001	1978-01-10	➤ Sign Up	Plexxikon Inc. (Berkeley, CA)	2035-12-07	RX		search
Genentech	RITUXAN	rituximab	VIAL	103705	001	1997-11-26	➤ Sign Up	Plexxikon Inc. (Berkeley, CA)	2035-12-07	RX		search
Genentech	HERCEPTIN	trastuzumab	VIAL; INTRAVENOUS	103792	001	1998-09-25	➤ Sign Up	Plexxikon Inc. (Berkeley, CA)	2035-12-07	RX	Orphan	search
Genzyme	CAMPATH	alemtuzumab	VIAL; INTRAVENOUS	103948	001	2001-05-07	➤ Sign Up	Plexxikon Inc. (Berkeley, CA)	2035-12-07	RX	Orphan	search
Genzyme	CAMPATH	alemtuzumab	VIAL; INTRAVENOUS	103948	002	2001-05-07	➤ Sign Up	Plexxikon Inc. (Berkeley, CA)	2035-12-07	RX	Orphan	search
Genzyme	LEMTRADA	alemtuzumab	INJECTABLE;INJECTION	103948	003	2001-05-07	➤ Sign Up	Plexxikon Inc. (Berkeley, CA)	2035-12-07	RX	Orphan	search
Spectrum Pharms	ZEVALIN	ibritumomab tiuxetan	INJECTABLE; INJECTION	125019	001	2002-02-19	➤ Sign Up	Plexxikon Inc. (Berkeley, CA)	2035-12-07	RX	Orphan	search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patent Family for US Patent 9,938,273

Subscribe to access the full database, or try a Free Trial
Country	Patent Number	Publication Date
Australia	2016367147	Jul 05, 2018
Brazil	112018011475	Dec 04, 2018
Canada	3007462	Jun 15, 2017
China	108368110	Aug 03, 2018
Colombia	2018007052	Jul 19, 2018
European Patent Office	3386980	Oct 17, 2018
Israel	259803	Jul 31, 2018
>Country	>Patent Number	>Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.